Nanologica’s interim report for Q2 2026 will be published on Monday 31 August, instead of 20 August as previously announced. As a result of the acquisition of Syntagon, the company is carrying out an extended validation of the consolidated financial statements. 2026-08-17 Nanologica AB Changes Dates for Interim Report
In Chromatography, Nanologica aims to make insulin and other diabetes drugs available to more patients in need by lowering the manufacturing costs. Thanks to Nanologica’s proprietary silica manufacturing process, the company can provide products with high performance as well as chemical and mechanical stability. This results in lower production costs for the company’s customers as the products last longer and make the purification process more efficient.
Nanologica’s purification media NLAB Saga® has been developed to meet the requirements of industrial purification, primarily to suit purification processes for insulin and other peptides.
Nanologica focuses its Drug Development business on inhaled drugs and respiratory diseases. The company’s platform technology is being developed both in internal projects and together with pharmaceutical partners, to reformulate active pharmaceutical ingredients, APIs, that in current formulations do not provide optimal treatment for patients.
By reformulating clinically proven APIs into inhaled formulations, Nanologica may significantly improve patients’ quality of life and/or enable local treatment to the lung where today only systemic treatment is available. The goal is to provide a platform technology that enables improved or completely new treatments for patients with severe lung diseases.
Nanologica AB (publ) has appointed Axel Elner as new CFO. Axel Elner will take up the position on 10 November 2026. Axel Elner joins Nanologica from Viaplay Group AB and the role as Vice President Integration where he has led the integration of Allente into Viaplay Group with responsibility for executing cost synergies, operational integration
Nanologica’s Chief Financial Officer Eva Osterman has decided to leave the company. Eva will remain in the Group until 31 August 2026 to ensure a smooth handover and support the recruitment of her successor. The recruitment process has begun. “Since she started in 2017, Eva has had a central role in the company and been
Vd Andreas Bhagwani intervjuas om Nanologicas Q1-rapport. Intervjun gjordes 22 maj 2026. Rapporten i sin helhet finns här: Svenska Engelska
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Company presentation made by CEO Andreas Bhagwani on August 24, 2022.
For more videos about the company as well as video presentations of interim reports, please refer to Investor Relations.
